| Literature DB >> 29796216 |
Fatemeh Forouzanfar1, Hossein Hosseinzadeh2,3.
Abstract
Chronic neuropathic pain is a common significant and debilitating problem that presents a major challenge to health-care. Despite the large number of available drugs, there are no curative conventional treatments for neuropathic pain. Nowadays, more attention has been focused on the herbal formulation in the field of drug discovery. Therefore, we performed an extensive review about herbal drugs and plants that exhibited protective effects on neuropathic pain. In this review, the beneficial effects of each plant in different neuropathic pain model, either in animals or in patients are reported. Moreover, the possible involved mechanisms for the protective effects are discussed. The more common plants which are used for the treatment of neuropathic pain are included as: Acorus calamus, Artemisia dracunculus, Butea monosperma, Citrullus colocynthis, Curcuma longa, Crocus sativus, Elaeagnus angustifolia, Ginkgo biloba, Mitragyna speciosa, Momordica charantia, Nigella sativa, Ocimum sanctum, Phyllanthus amarus, Pterodon pubescens Benth, Rubia cordifolia and Salvia officinalis. Furthermore, the most pathways which are known to be involved in pain relief by means of herbal remedies are anti-oxidant activity, anti-inflammatory, anti-apoptotic, neuroprotective and calcium inhibitory actions. In conclusion, this review suggests that some herbal plants can be suitable candidates for the treatment of neuropathic pain.Entities:
Keywords: Analgesic; Antinociceptive; Chronic pain; Herbal medicine Neuropathic pain
Year: 2018 PMID: 29796216 PMCID: PMC5960749 DOI: 10.22038/IJBMS.2018.24026.6021
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Herbal medicines and their constituents tested for neuropathic pain in human studies
| Substance | Neuropathic disorders | Study type | Results | References |
|---|---|---|---|---|
| A9-Tetrahydrocannabinol/Cannabidiol (THC/CBD) | HIV-associated distal sensory predominant polyneuropathy | Phase II, double-blind, placebo-controlled, crossover trial | Reduced neuropathic pain intensity | ( |
| THC/CBD | Central neuropathic pain in patients with multiple sclerosis | Randomized controlled trials | Improvement in neuropathic pain without evidence of tolerance | ( |
| THC/CBD | Patients with intractable cancer-related pain | Multicenter, double-blind, randomized, placebo-controlled, parallel-group study | Reduced neuropathic pain | ( |
| THC/CBD | Patients with terminal cancer-related pain refractory to strong opioid analgesics | An open-label extension study | Well tolerated and reduced pain | ( |
| THC/CBD | Patients with peripheral neuropathic pain | A double-blind, randomized, placebo-controlled, parallel group study | Improvement in neuropathic pain | ( |
| THC/CBD | Patients with peripheral neuropathic pain | A multicentre, open-label, follow-on study | Improvement in neuropathic pain | ( |
| Aconitum | Patients with diabetic peripheral neuropathic pain | Controlled clinical trials study | Reduced diabetic peripheral neuropathic pain | ( |
| Painful diabetic polyneuropathy patients | Double-blind randomized placebo-controlled clinical trial | Reduced diabetic polyneuropathy pain | ( | |
| Goshajinkigan | Oxaliplatin-induced neuropathy patients | Phase 2, multicenter, randomized, double-blind, placebo-controlled trial | Delayed the onset of grade 2 or greater oxaliplatin-induced neuropathy | ( |
NMDA: N-methyl-D-aspartate; CNS: central nervous system; PNS: peripheral nervous system; STZ: streptozotocin; ROS: reactive oxygen species; CIPN: chemotherapy drugs that induce peripheral neuropathy; HAE-AC: hydroalcoholic extract of A. calamus; MPO: myeloperoxidase; TST: tibial and sural nerve transection; CCI: chronic constriction injury; TBARS: thiobarbituric acid reactive substances; GSH: glutathione; PDPN: painful diabetic polyneuropathy; 6-OHDA: 6-Hydroxydopamine; PCPA: p-chlorophenylalanine; COX-2: cyclooxygenase 2; MDA: malondialdehyde; SNL: spinal nerve ligation; NOS: nitric oxide synthase; PSNL: partial sciatic nerve ligation; EEPp: ethanolic extract from P. pubescens fruits; THC/CBD, A9-Tetrahydrocannabinol/Cannabidiol; DRG: dorsal root ganglion; 3α-HSOR: 3α-Hydroxysteroid oxidoreductase; SOD: superoxide dismutase
Mechanisms of actions of herbal medicines against neuropathic pain in animal models
| Substance | Animal model | Mechanisms of actions | References |
|---|---|---|---|
| Partial sciatic nerve ligation (PSNL) in mice | Inhibition of proinflammatory cytokines, glutamatergic receptors as well as TRPV1 and TRPA1 channels | ( | |
| Spinal nerve injury (SNI) in rat | Microglial β-endorphin expression via p38 MAPK signaling | ( | |
| Streptozotocin (STZ)-induced diabetes in rat | Modulation of oxidative–nitrosative stress | ( | |
| PMI-5011 | High-fat diet-induced neuropathy in mice | Inhibition of oxidative nitrosative stress and lipoxygenase activation | ( |
| Paclitaxel-induced neuropathic pain in rat | Involvement of GABA or antioxidant mechanism | ( | |
| EGb 761 | SNL in rat | Anti-inflammatory, antioxidant effect, a platelet activating factor antagonist and a protective effect against NMDA. | ( |
| Vincristine-induced neuropathic pain in rat | Decrement of oxidative stress and calcium levels | ( | |
| Tibial and sural nerve transection (TST) in rat | Anti-inflammatory, antioxidant, and neuroprotective actions | ( | |
| Chronic constriction injury (CCI) in rat | Anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory actions | ( | |
| Vincristine-induced neuropathic pain in rat | Anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory actions | ( | |
| Vincristine-induced neuropathic pain in mice | Anti-inflammatory effects | ( | |
| Koumine | CCI in rat | Elevated allopregnanolone levels through allosteric modulation of GABAA and by suppressing the release of microglia activation-induced inflammatory cytokines | ( |
| Incarvillateine | Complete Freund’s Adjuvant (CFA), SNI and paclitaxel induced neuropathic pain in mice | Activation of the adenosine system | ( |
| Curcumin | CCI in mice | Descending monoamine system (coupled with spinal β2-adrenoceptor and 5-HT1A receptor) | ( |
| Curcumin | CCI in rat | Decrement the serum level of COX-2 | ( |
| CFA, PSNL in mice | Anti-inflammatory action | ( | |
| CCI in rat | Mediated by vanilloid receptors TRPV1. | ( | |
| TST in rat | PPAR-gamma agonistic activity, anti-inflammatory, & antioxidative effects. | ( | |
| lappaconitine | CCI in rat | Regulating the purinergic signaling system at DRG level | ( |
| Saffron’s extracts and safranal | CCI in rat | Antioxidant effects. | ( |
| MGM-16 | PSNL in mice | Opioid agonistic effects | ( |
| STZ-induced diabetic in rat | Antioxidant actions | ( | |
| DA-9801 | STZ induced rat/mouse diabetic, db/db mouse model | Increasing the NGF level | ( |
| Naringin | STZ induced diabetic in rat | Antioxidant and antiapoptotic activity | ( |
| Quercetin | STZ induced diabetic in mice | Modulation of opioidergic system | ( |